Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur Journal of Neurol 2009;16: 968–981.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808. Also available from https://www.ichd-3.org/1-migraine/ (accessed 17 January 2018).
Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: classification and nomenclature. Headache. 2009;49:1206–1213.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;78(17):1337–45.
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–762.
Silberstein SD. Preventive Migraine Treatment. Continuum. 2015;21:973–989.
Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2016; 10;86(19):1818–26.
Steiner TJ, Martelletti P. Aids for management of common headache disorders in primary care. J Headache Pain. 2007;8(Suppl 1):S2.
Discover detailed migraine awareness with/without aura, HALT index, pathophysiology and the trigeminal system, symptoms including visual disturbances and nausea and diagnosis from the International Classification of Headache Disorders 3 (ICHD-3).
Discover acute and preventive migraine treatment options following the AAN and AHS guidelines that include NSAIDs, triptans, ergotamine derivatives, opioids, beta-blockers, calcium channel blockers and tricyclic antidepressants. Future treatments detail CGRP antagonists.
Review the terms used in the Migraine Knowledge Centre, along with their definitions including cortical spreading depression, Headache-Attributed Lost Time index (HALT), Hemiplegic migraine and vagus nerve stimulation.